SAN DIEGO, June 3, 2011 (GLOBE NEWSWIRE) -- Bassam Damaj, PhD., Chief Executive Officer of Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) ( http://www.apricusbio.com ) announced today that he will discuss plans for the commercialization of Vitaros®, the Company's topical erectile dysfunction drug, during his presentation at the Jefferies 2011 Global Healthcare Conference. Dr. Damaj's presentation date and time have been changed, and will now take place on June 8, 2011 at 2:00pm, at the Grand Hyatt Hotel in New York.
Vitaros® is approved for sale in Canada and is expected to be on the market in that country during the second half of 2011. Dr. Damaj will also review the Company's recent marketing application filing for Vitaros® in Europe, as well as expectations for filing a marketing application in Switzerland. Vitaros® utilizes Apricus Bio's NexACT® drug delivery technology, which enables the rapid absorption of various active pharmaceutical ingredients through the skin, with the goal of improving patient outcomes and reducing side effects.
Dr. Damaj's presentation at the Jefferies conference will be webcast and accessible to the public online at http://www.wsw.com/webcast/jeff60/apri/ or via the Apricus Bio's web site at . A replay will be available for 90 days after the presentation.
Other drugs in Apricus Bio's pipeline include: Femprox®, a treatment for female sexual arousal disorder; MycoVa™, for onychomycosis (nail fungus); PrevOnco™, a treatment for hepatocellular liver carcinoma; and RayVa™, for Raynaud's Syndrome.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.
For further information on Apricus Bio, visit and for information on its subsidiaries please visit or . You can also receive information at http://twitter.com/apricusbio and .
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further development products and product candidates, have such products and product candidates approved by relevant regulatory authorities, to successfully commercialize such products and product candidates and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT: Apricus Biosciences, Inc. Edward Cox, V.P. Corporate Development & Investor Relations (858) 848-4249 ecox@apricusbio.com Apricus Bio Investor Relations Paula Schwartz Rx Communications Group, LLC (917) 322-2216 pschwartz@rxir.com